Q-omics provides the consensus-scored HSP90AA5P profile across patient tissues and cancer cell-line models. HSP90AA5P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, HSP90AA5P is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, HSP90AA5P RNA expression shows 15,820 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, HNSC, and THYM as cancer lineages where HSP90AA5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSP90AA5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSP90AA5P survival associations across molecular data types. HSP90AA5P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSP90AA5P RNA expression–survival associations across cancer types. High HSP90AA5P expression shows unfavorable associations in COAD, ESCA, KIRC and READ, but favorable associations in CESC and GBM. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify CESC as the clearest survival context for HSP90AA5P RNA expression.
This table summarizes HSP90AA5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for HSP90AA5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSP90AA5P shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in HNSC, LUSC and BLCA. The HNSC box plot shows higher HSP90AA5P RNA expression in tumor versus normal tissue (log2 FC = +0.165, t-test p = .001).
This table shows molecular features associated with HSP90AA5P in patient tissues and cancer cell lines. In patient samples, HSP90AA5P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
